📷 Image: Wikimedia Commons / Unknown authorUnknown author
Health
CDSCO adds bullous pemphigoid to Teneligliptin safety warning
✍️ Telangana Today
🗓 04 Oct 2026, 05:02 PM
👁 18
The Central Drugs Standard Control Organization has updated the safety label of Teneligliptin to list bullous pemphigoid as a reported adverse effect, according to Telangana Today.
The Central Drugs Standard Control Organization (CDSCO) has issued a new safety warning for the anti‑diabetic drug Teneligliptin, adding bullous pemphigoid to its list of reported adverse reactions.
The amendment appears in the latest update of the drug's safety information, which will be reflected in prescribing guidelines and package inserts.
The change was reported by Telangana Today, indicating that healthcare providers should monitor patients on Teneligliptin for signs of this rare skin disorder.
The amendment appears in the latest update of the drug's safety information, which will be reflected in prescribing guidelines and package inserts.
The change was reported by Telangana Today, indicating that healthcare providers should monitor patients on Teneligliptin for signs of this rare skin disorder.